NDA Partners LLC: A Development Partner to Biopharmaceutical Investors and Companies

David Jacobson-Kram, PhD, DABT

Practice Area Focus

  • Development Strategy
  • Regulatory Strategy
  • Toxicology
  • Genetic Toxicology
  • Cellular Toxicology
  • Mammalian Toxicology


David Jacobson-Kram joined NDA Partners as a Premier Expert consultant in 2014. He formerly served as the Associate Director of Pharmacology and Toxicology in the U.S. Food & Drug Administration (FDA) Office of New Drugs (CDER). Prior to his 11 years at FDA, Dr. Jacobson-Kram was Vice President of Toxicology and Laboratory Animal Diagnostics at BioReliance Corporation; Associate Professor of Oncology, Department of Radiobiology, The Johns Hopkins University Oncology Center; and Acting Branch Chief, Genetic and Molecular Toxicology Assessment Branch, Office of Health and Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency.

Over the past twenty years, Dr. Jacobson-Kram has served as principal and co-principal investigator on several NIH grants and government contracts and published widely in the areas of genetic and molecular toxicology. He has served as council member, treasurer and chairman of the Genetic Toxicology Association, executive council member to the Environmental Mutagen Society, and Editor of Cell Biology and Toxicology. In 1996 he became a Diplomate of the American Board of Toxicology (DABT). He earned his PhD in Developmental Biology from the University of Connecticut.